Host-derived interleukin-1α is important in determining the immunogenicity of 3-methylcholantrene tumor cells

Journal of Immunology

Volumn 182, Issue 8, 2009, Pages 4874-4881

  Elkabets, Moshe ^a   Krelin, Yakov ^a   Dotan, Shahar ^a   Cerwenka, Adelheid ^b   Porgador, Angel ^a   Lichtenstein, Rachel G ^a   White, Malka R ^a   Zoller, Margot ^c   Iwakura, Yoichizo ^e   Dinarello, Charles A ^d   Voronov, Elena ^a   Apte, Ron N ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Department of Tumor Progression and Tumor Defense ^*  (Germany)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTRENE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHYL GROUP; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; 3 METHYLCHOLANTHRENE; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NEOPLASM; TUMOR CELL CULTURE;

ANIMALS; BIOLOGICAL MARKERS; FEMALE; IMMUNITY, INNATE; INTERLEUKIN-1ALPHA; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 65249096761     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803916     Document Type: Article

References (49)

1. Apte, R. N., S. Dotan, M. Elkabets, M. R. White, E. Reich, Y. Carmi, X. Song, T. Dvozkin, Y. Krelin, and E. Voronov. 2006. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25: 387-408.
2. Apte, R. N., and E. Voronov. 2008. Is interleukin-1 a good or bad "guy" in tumor immunobiology and immunotherapy? Immunol. Rev. 222: 222-241.
3. de Visser, K. E., and L. M. Coussens. 2006. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 13: 118-137.
4. Lin, W. W., and M. Karin. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117: 1175-1183. (Pubitemid 46718402)
5. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related in- flammation. Nature 454: 436-444.
6. Pikarsky, E., and Y. Ben-Neriah. 2006. NF-κB inhibition: a double-edged sword in cancer? Eur. J. Cancer 42: 779-784.
7. Murdoch, C., M. Muthana, S. B. Coffelt, and C. E. Lewis. 2008. The role of myeloid cells in the promotion of tumor angiogenesis. Nat. Rev. Cancer 8: 618-631.
8. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
9. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
10. Swann, J. B., and M. J. Smyth. 2007. Immune surveillance of tumors. J. Clin. Invest. 117: 1137-1146.
11. Ostrand-Rosenberg, S. 2008. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet Dev. 18: 11-18. (Pubitemid 351694442)
12. Bui, J. D., and R. D. Schreiber. 2007. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19: 203-208.
13. Kim, R., M. Emi, and K. Tanabe. 2007. Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14. (Pubitemid 46537674)
14. Reiman, J. M., M. Kmieciak, M. H. Manjili, and K. L. Knutson. 2007. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 17: 275-287. (Pubitemid 47211962)
15. Apte, R. N., Y. Krelin, X. Song, S. Dotan, E. Recih, M. Elkabets, Y. Carmi, T. Dvorkin, R. M. White, L. Gayvoronsky, et al. 2006. Effects of micro-environment-and malignant cell-derived interleukin-1 in carcinogenesis, tumor invasiveness and tumor-host interactions. Eur. J. Cancer 42: 751-759.
16. Arend, W. P. 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13: 323-340.
17. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
18. Mantovani, A., M. Muzio, P. Ghezzi, C. Colotta, and M. Introna. 1998. Regulation of inhibitory pathways of the interleukin-1 system. Ann. NY Acad. Sci. 840: 338-351. (Pubitemid 28302060)
19. Sims, J. E. 2002. IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. 14: 117-122.
20. Stylianou, E., and J. Saklatvala. 1998. Interleukin-1. Int. J. Biochem. Cell Biol. 30: 1075-1079.
21. Krelin, Y., E. Voronov, S. Dotan, M. Elkabets, E. Reich, M. Fogel, M. Huszar, Y. Iwakura, S. Segal, C. A. Dinarello, and R. N. Apte. 2007. Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67: 1062-1071. (Pubitemid 46270762)
22. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J. Immunol. 175: 8200-8208.
23. Song, X., E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Bjorkdahl, S. Segal, C. A. Dinarello, and R. N. Apte. 2003. Differential effects of IL-1 α and IL-1 β on tumorigenicity patterns and invasiveness. J. Immunol. 171: 6448-6456. (Pubitemid 37532073)
24. Marhaba, R., I. Nazarenko, D. Knofler, E. Reich, E. Voronov, M. Vitacolonna, D. Hildebrand, E. Elter, R. N. Apte, and M. Zoller. 2008. Opposing effects of fibrosarcoma cell-derived IL-1α and IL-1β on immune response induction. Int. J. Cancer 123: 134-145. (Pubitemid 351705201)
25. Nazarenko, I., R. Marhaba, E. Reich, E. Voronov, M. Vitacolonna, D. Hildebrand, E. Elter, M. Rajasagi, R. N. Apte, and M. Zoller. 2008. Tumorigenicity of IL-1α- and IL-1β-deficient fibrosarcoma cells. Neoplasia 10: 549-562. (Pubitemid 351770299)
26. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
27. Douvdevani, A., M. Huleihel, M. Zoller, S. Segal, and R. N. Apte. 1992. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 α either spontaneously or following IL-1 α gene transfer. Int. J. Cancer 51: 822-830.
28. Voronov, E., Y. Weinstein, D. Benharroch, E. Cagnano, R. Ofir, M. Dobkin, R. M. White, M. Zoller, V. Barak, S. Segal, and R. N. Apte. 1999. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression. Cancer Res. 59: 1029-1035. (Pubitemid 29135962)
29. Zoller, M., A. Douvdevani, S. Segal, and R. N. Apte. 1992. Interleukin-1 production by transformed fibroblasts, II: influence on antigen presentation and T-cell-mediated anti-tumor response. Int. J. Cancer 50: 450-457.
30. Zoller, M., A. Douvdevani, S. Segal, and R. N. Apte. 1992. Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection. Int. J. Cancer 50: 443-449.
31. Dvorkin, T., X. Song, S. Argov, R. M. White, M. Zoller, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte. 2006. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1α. J. Leukocyte Biol. 80: 96-106. (Pubitemid 44835530)
32. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
33. Smyth, M. J., G. P. Dunn, and R. D. Schreiber. 2006. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90: 1-50.
34. Horai, R., M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, and Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187: 1463-1475. (Pubitemid 28215405)
35. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T. I. Arnon, Y. Bushkin, D. M. Davis, J. L. Strominger, J. W. Yewdell, and A. Porgador. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409: 1055-1060. (Pubitemid 32204059)
36. Cerwenka, A., A. B. Bakker, T. McClanahan, J. Wagner, J. Wu, J. H. Phillips, and L. L. Lanier. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12: 721-727.
37. Gazit, R., R. Gruda, M. Elboim, T. I. Arnon, G. Katz, H. Achdout, J. Hanna, U. Qimron, G. Landau, E. Greenbaum, et al. 2006. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7: 517-523.
38. Townsend, M. J., A. S. Weinmann, J. L. Matsuda, R. Salomon, P. J. Farnham, C. A. Biron, L. Gapin, and L. H. Glimcher. 2004. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 20: 477-494.
39. Blankenstein, T., and Z. Qin. 2003. Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv. Cancer Res. 90: 179-207. (Pubitemid 37549225)
40. Qin, Z., H. J. Kim, J. Hemme, and T. Blankenstein. 2002. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon γ receptor-dependent foreign body reaction. J. Exp. Med. 195: 1479-1490. (Pubitemid 34602825)
41. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. R. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
42. Unni, A. M., T. Bondar, and R. Medzhitov. 2008. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc. Natl. Acad. Sci. USA 105: 1686-1691.
43. Werneck, M. B., G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher. 2008. T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J. Immunol. 180: 8004-8010.
44. Robbins, S. H., M. S. Tessmer, L. Van Kaer, and L. Brossay. 2005. Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation. Eur. J. Immunol. 35: 757-765.
45. Berzofsky, J. A., and M. Terabe. 2008. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180: 3627-3635.
46. Chen, C. J., H. Kono, D. Golenbock, G. Reed, S. Akira, and K. L. Rock. 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13: 851-856.
47. Nakae, S., M. Asano, R. Horai, and Y. Iwakura. 2001. Interleukin-1 β, but not interleukin-1 α, is required for T-cell-dependent antibody production. Immunology 104: 402-409. (Pubitemid 34037832)
48. Nakae, S., C. Naruse-Nakajima, K. Sudo, R. Horai, M. Asano, and Y. Iwakura. 2001. IL-1 α, but not IL-1 β, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. Int. Immunol. 13: 1471-1478. (Pubitemid 33133876)
49. Nambu, A., S. Nakae, and Y. Iwakura. 2006. IL-1β, but not IL-1α, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses. Int. Immunol. 18: 701-712. (Pubitemid 43779060)